ArticleJournal of virology2012
Human CD4+ T cell response to human herpesvirus 6.
Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 63 citations in OpenAlex.
- Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.Science translational medicine · 2014Trial
- CD4Science translational medicine · 2026Article
- TCR repertoire of human cytotoxic CD4 T cells responding to betaherpesviruses HHV-6B and HCMV.Frontiers in immunology · 2025Article
- Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India.Scientific reports · 2024Article
- Human herpesvirus 6-specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients.Blood advances · 2023Observational
- The persistent viral infections in the development and severity of myalgic encephalomyelitis/chronic fatigue syndrome.Journal of translational medicine · 2023Article
- The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek's disease virus peptides by using an unprecedented binding motif.PLoS biology · 2021Article
- Review
- Genome-Wide Approach to the CD4 T-Cell Response to Human Herpesvirus 6B.Journal of virology · 2019Article
- Phenotypic and Functional Differences between Human Herpesvirus 6- and Human Cytomegalovirus-Specific T Cells.Journal of virology · 2019Article
- Identification of CD4 and H-2KScientific reports · 2019Article
- RNA Sequencing of theJournal of virology · 2019Article
- HHV-6B infection, T-cell reconstitution, and graft-vs-host disease after hematopoietic stem cell transplantation.Bone marrow transplantation · 2018Review
- Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).Journal of translational medicine · 2018Review
- Cross-sectional analysis of CD8 T cell immunity to human herpesvirus 6B.PLoS pathogens · 2018Article
- Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus.Journal of virology · 2018Article
- Advances in the Characterization of the T-Cell Response to Human Herpesvirus-6.Frontiers in immunology · 2018Review
- Lymphoproliferative Syndromes Associated with Human Herpesvirus-6A and Human Herpesvirus-6B.Mediterranean journal of hematology and infectious diseases · 2018Review
- Human Herpesvirus 6B Downregulates Expression of Activating Ligands during Lytic Infection To Escape Elimination by Natural Killer Cells.Journal of virology · 2016Article
- Identification of novel CD8+ T cell epitopes in human herpesvirus 6B U11 and U90.Immunity, inflammation and disease · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Following primary infection, human herpesvirus 6 (HHV-6) establishes a persistent infection for life. HHV-6 reactivation has been associated with transplant rejection, delayed engraftment, encephalitis, muscular dystrophy, and drug-induced hypersensitivity syndrome. The poor understanding of the targets and outcome of the cellular immune response to HHV-6 makes it difficult to outline the role of HHV-6 in human disease. To fill in this gap, we characterized CD4 T cell responses to HHV-6 using peripheral blood mononuclear cell (PBMC) and T cell lines generated from healthy donors. CD4(+) T cells responding to HHV-6 in peripheral blood were observed at frequencies below 0.1% of total T cells but could be expanded easily in vitro. Analysis of cytokines in supernatants of PBMC and T cell cultures challenged with HHV-6 preparations indicated that gamma interferon (IFN-γ) and interleukin-10 (IL-10) were appropriate markers of the HHV-6 cellular response. Eleven CD4(+) T cell epitopes, all but one derived from abundant virion components, were identified. The response was highly cross-reactive between HHV-6A and HHV-6B variants. Seven of the CD4(+) T cell epitopes do not share significant homologies with other known human pathogens, including the closely related human viruses human herpesvirus 7 (HHV-7) and human cytomegalovirus (HCMV). Major histocompatibility complex (MHC) tetramers generated with these epitopes were able to detect HHV-6-specific T cell populations. These findings provide a window into the immune response to HHV-6 and provide a basis for tracking HHV-6 cellular immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.